ArticleAmerican journal of cancer research2020

Cost-effectiveness analysis of nivolumab compared to pembrolizumab in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck.

Justin Yeh et al.PubMed ↗Full text ↗

No numbers read from the abstract.